Head-to-head evidence
aleniglipron vs efpeglenatide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
aleniglipron
Developed by Structure Therapeutics
NCT05762471 · Phase 1/2 · completed
The study randomized 142 participants to GSBR-1290 or placebo with participants, care providers, and investigators masked. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Registered primary endpoint is safety/tolerability; the weight results are the phase 2a obesity cohort's efficacy readout from the sponsor's SEC-filed topline release, not yet peer reviewed.
Next expected readout: September 2028 · NCT07654374 (registry estimate)
efpeglenatide
Developed by Hanmi Pharmaceutical and partners
NCT03353350 · Phase 3 · completed
The trial was randomized, quadruple-blinded, placebo-controlled, and included 406 participants, providing a strong comparative design. However, the primary endpoint was the surrogate measure of HbA1c change, and although the reported changes favored efpeglenatide, statistical significance for the primary comparison was not reported.
Next expected readout: November 2027 · NCT07379333 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: aleniglipron's landscape · efpeglenatide's landscape